To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
Initiator Pharma completes dosing in Phase 2a trial with IP2018
Initiator Pharma A/S, a clinical-stage biotech company, today announced that it has completed dosing all 24 patients for its Phase 2a clinical trial with IP2018. Draft results are expected end of Q2 2023, as previously communicated.
Initiator Pharma har slutfört dosering i fas 2a-studien med IP2018
Initiator Pharma A/S, ett läkemedelsbolag i klinisk fas, meddelade idag att doseringen slutförts av samtliga 24 patienter i bolagets kliniska fas 2a-studie med IP2018. Som tidigare kommunicerats förväntas preliminära resultat i slutet av Q2 2023.